Neogenomics Inc
NASDAQ:NEO
Intrinsic Value
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. [ Read More ]
The intrinsic value of one NEO stock under the Base Case scenario is 12.21 USD. Compared to the current market price of 14.03 USD, Neogenomics Inc is Overvalued by 13%.
Valuation Backtest
Neogenomics Inc
Run backtest to discover the historical profit from buying and selling NEO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Neogenomics Inc
Current Assets | 596.8m |
Cash & Short-Term Investments | 415.2m |
Receivables | 131.3m |
Other Current Assets | 50.3m |
Non-Current Assets | 1.1B |
PP&E | 183.8m |
Intangibles | 895.9m |
Other Non-Current Assets | 4.7m |
Current Liabilities | 96.3m |
Accounts Payable | 20.3m |
Accrued Liabilities | 73.8m |
Other Current Liabilities | 2.1m |
Non-Current Liabilities | 643.4m |
Long-Term Debt | 538.2m |
Other Non-Current Liabilities | 105.2m |
Earnings Waterfall
Neogenomics Inc
Revenue
|
591.6m
USD
|
Cost of Revenue
|
-347m
USD
|
Gross Profit
|
244.6m
USD
|
Operating Expenses
|
-341.3m
USD
|
Operating Income
|
-96.6m
USD
|
Other Expenses
|
8.7m
USD
|
Net Income
|
-88m
USD
|
Free Cash Flow Analysis
Neogenomics Inc
NEO Profitability Score
Profitability Due Diligence
Neogenomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Neogenomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
NEO Solvency Score
Solvency Due Diligence
Neogenomics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Neogenomics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NEO Price Targets Summary
Neogenomics Inc
According to Wall Street analysts, the average 1-year price target for NEO is 21.98 USD with a low forecast of 18.18 USD and a high forecast of 31.5 USD.
Ownership
NEO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NEO Price
Neogenomics Inc
Average Annual Return | 5.51% |
Standard Deviation of Annual Returns | 73.84% |
Max Drawdown | -89% |
Market Capitalization | 1.8B USD |
Shares Outstanding | 127 610 000 |
Percentage of Shares Shorted | 7.88% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,000 full-time employees. The company went IPO on 2012-12-10. The firm operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The company operates testing laboratories in United States, Europe and Asia.
Contact
IPO
Employees
Officers
The intrinsic value of one NEO stock under the Base Case scenario is 12.21 USD.
Compared to the current market price of 14.03 USD, Neogenomics Inc is Overvalued by 13%.